Search
2-deoxyglucose
go.drugbank.com/drugs/DB08831InvestigationalAs an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. … 2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel).
Synonyms: 2-DG, 2-deoxy-D-glucoseIsoeugenol
go.drugbank.com/drugs/DB14188ApprovedIt is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278]. … Isoeugenol is a commonly used fragrance added to many commercially available products, and occurs naturally in the essential oils of plants such as ylang-ylang.
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalAt low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalAlthough corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis. … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production.
Categories: Compounds used in a research, industrial, or household settingSemaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalas the first approved drug for such use since 2014. … Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.
Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test. … RAS variants rather than a single mutation.
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5. … Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalLike other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis [L1396]. … Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexCamizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist. … Camizestrant is an oral selective estrogen receptor degrader (SERD) and estrogen receptor (ER) antagonist used in combination with a CDK4/6 inhibitor to treat hormone receptor-positive, HER2-negative locally
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIts indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence. … Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).